Neuromuscular Junctions

Learning Outcomes

• By the end of this session, students should be able to:

  • Identify and categorize drugs that target the neuromuscular junction (NMJ).

  • Describe the molecular mechanisms and physiological consequences of these drugs.

  • Understand the pathophysiology of NMJ-related autoimmune disorders.

The Neuromuscular Junction (NMJ)

1. Overview: The NMJ is a highly specialized chemical synapse between a motor neuron and a skeletal muscle fiber. It converts electrical signals (action potentials) from the nervous system into mechanical contraction.

2. Clinical Relevance: Understanding the NMJ is vital for anesthesia (using muscle relaxants), managing autoimmune diseases, and responding to neurotoxicological emergencies (e.g., nerve gas exposure).

Peripheral Nervous System (PNS) Organization

• Autonomic Nervous System (ANS)

  • Function: Involuntary regulation of smooth muscles, cardiac muscles, and gland secretion.

  • Pathway: Typically involves a two-neuron chain (pre-ganglionic and post-ganglionic).

  • Regulation: Primarily controlled by the hypothalamus and brain stem centers.

• Somatic Nervous System (SNS)

  • Function: Voluntary control of skeletal muscle contraction.

  • Pathway: A single motor neuron extends from the CNS (spinal cord ventral horn) directly to the effector muscle.

  • Regulation: Controlled by the primary motor cortex via corticospinal tracts.

Detailed Glandular Terminology

• Exocrine Glands: Utilize ducts to transport secretions (such as enzymes or sweat) to epithelial surfaces.

• Endocrine Glands: Ductless glands that secrete hormones directly into the interstitial fluid, which then enter the systemic circulation.

Acetylcholine (ACh) Lifecycle

• Synthesis: Occurs in the axon terminal cytosol.

  • Reaction: $\text{Choline}+{Acetyl-CoA}\xrightarrow{\text{Choline Acetyltransferase (ChAT)}}\text{ACh}+\text{CoA}$

  • ACh is then transported into synaptic vesicles by the Vesicular Acetylcholine Transporter (VAChT).

• Degradation: Rapidly occurs in the synaptic cleft to prevent constant muscle stimulation.

  • Reaction: $\text{ACh} \xrightarrow{\text{Acetylcholinesterase (AChE)}} \text{Acetate} + \text{Choline}$

  • Recycling: Choline is transported back into the presynaptic terminal via a high-affinity Naⁱ-dependent choline transporter (CHT).

NMJ Structure and Transmission Mechanism

• Structural Components:

  • Presynaptic Terminal: Contains mitochondria and synaptic vesicles filled with ACh ($\sim 10,000$ molecules per vesicle).

  • Synaptic Cleft: A $\sim 20-50$ nm gap containing the basal lamina and AChE.

  • Postsynaptic Motor End-Plate: Folded membrane (junctional folds) to increase surface area, densely packed with nicotinic ACh receptors (nAChR).

• The Transmission Sequence:

  1. Action Potential Arrival: Depolarizes the presynaptic terminal.

  2. Calcium Influx: Opens P/Q-type voltage-gated calcium channels (VGCC). $Ca^{2+}$ enters the terminal down its electrochemical gradient.

  3. Exocytosis: $Ca^{2+}$ binds to synaptotagmin, triggering SNARE protein-mediated fusion of vesicles with the plasma membrane, releasing ACh quanta.

  4. ACh Binding: ACh molecules diffuse across the cleft and bind to the two $\alpha$-subunits of the pentameric nAChR.

  5. End-Plate Potential (EPP): nAChRs are ligand-gated ion channels; binding allows $\text{Na}^{+}$ influx and $\text{K}^{+}$ efflux. The net inward current causes local depolarization (EPP).

  6. Excitation-Contraction Coupling: If the EPP reaches threshold, voltage-gated $\text{Na}^{+}$ channels in the sarcolemma open, triggering a muscle action potential. This travels down T-tubules, activating DHP receptors linked to Ryanodine receptors in the Sarcoplasmic Reticulum (SR), releasing stored $Ca^{2+}$ into the sarcoplasm to initiate contraction.

Neuromuscular Junction Disorders

1. Myasthenia Gravis (MG)

   • Pathology: Postsynaptic autoimmune attack. Antibodies bind to, block, or cause the internalization of nAChR.

   • Symptoms: Fatiguable muscle weakness, ptosis (eyelid drooping), and diplopia (double vision). Symptoms worsen with exertion.

2. Lambert-Eaton Myasthenic Syndrome (LEMS)

   • Pathology: Presynaptic autoimmune attack. Antibodies target P/Q-type VGCC, reducing $Ca^{2+}$ influx and ACh release.

   • Symptoms: Proximal muscle weakness that often improves temporarily with repeated exercise (due to calcium buildup in the terminal).

3. Neuromyotonia (Isaac's Syndrome)

   • Pathology: Antibodies against presynaptic voltage-gated potassium channels (VGKC). Failure of repolarization leads to repetitive firing of the motor nerve.

   • Symptoms: Continuous muscle fiber activity, twitching (fasciculations), and stiffness.

Pharmacology of the NMJ

Neuromuscular Blocking Agents (NMBAs)

• Non-depolarizing (Competitive Antagonists):

  • Examples: Tubocurarine, Pancuronium, Vecuronium.

  • Mechanism: Compete with ACh for nAChR binding sites. They do not activate the channel. Blockage can be overcome by increasing ACh concentration (e.g., using an AChE inhibitor).

• Depolarizing (Agonists):

  • Example: Succinylcholine ($\text{Suxamethonium}$).

  • Mechanism: Acts as a persistent nAChR agonist. It causes an initial contraction (fasciculation) followed by prolonged depolarization of the end-plate, which prevents the muscle from resetting (Phase I block). Eventually, the receptor may become desensitized (Phase II block).

Presynaptic Inhibitors (Experimental/Toxins)

• Hemicholinium: Blocks the CHT transporter, depleting choline stores and halting ACh synthesis.

• Vesamicol: Blocks VAChT, preventing the storage of ACh into vesicles.

• Botulinum Toxin: Cleaves SNARE proteins (e.g., SNAP-25), preventing vesicle fusion and ACh release. Causes flaccid paralysis.

Reversing Agents

• Anticholinesterases: Neostigmine and Pyridostigmine. By inhibiting AChE, they raise ACh levels in the cleft to displace non-depolarizing blockers.

• Sugammadex: A selective relaxant binding agent. It encapsulates rocuronium or vecuronium molecules in the plasma, rapidly reversing their effect.

Clinical Toxicology

• Organophosphates (Sarin, Pesticides): Irreversible inhibitors of AChE. Leads to a Cholinergic Crisis characterized by the mnemonic "SLUDGE" (Salivation, Lacrimation, Urination, Defecation, Gastric upset, Emesis) and eventually respiratory failure due to depolarizing paralysis of the diaphragm.

• Antidote: Atropine (to block muscarinic effects) and Pralidoxime (to reactivate AChE if administered before 'aging' occurs).